GT Biopharma, Inc. (57) | Note Agreements (18)
Recent Contracts
-
Form of December 2020 / January 2021 Note
(Filed With SEC on February 9, 2021)
-
Amendment to Convertible Note, effective as of January 31, 2021, by and between GT Biopharma, Inc. and Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
(Filed With SEC on February 9, 2021)
-
Form of December 2020 / January 2021 Note
(Filed With SEC on February 8, 2021)
-
Form of Securities Purchase Agreement - December 2020 / January 2021 Notes
(Filed With SEC on February 8, 2021)
-
Amendment to Settlement Note with Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
(Filed With SEC on February 8, 2021)
-
Form of Amendment to Convertible Note, dated as of January 31, 2021
(Filed With SEC on February 2, 2021)
-
CONVERTIBLE NOTE DUE JANUARY 31, 2021
(Filed With SEC on December 28, 2020)
-
AMENDMENT TO CONVERTIBLE NOTE & STANDSTILLAGREEMENT
(Filed With SEC on December 23, 2020)
-
Form of Settlement Note, dated November 9, 2020
(Filed With SEC on November 13, 2020)
-
Form of Secured Convertible Note
(Filed With SEC on November 9, 2020)
-
Form of Secured Convertible Note
(Filed With SEC on September 22, 2020)
-
Form of Secured Convertible Note
(Filed With SEC on July 9, 2020)
-
Form of Convertible Note, dated June 19, 2020 (included in Exhibit 10.1)
(Filed With SEC on June 19, 2020)
-
Form of Note, dated April/May, 2020
(Filed With SEC on May 15, 2020)
-
Form of Note, dated January 30, 2020
(Filed With SEC on May 15, 2020)
-
Form of Secured Convertible Note
(Filed With SEC on August 23, 2019)
-
CONVERTIBLE NOTE DUE NOVEMBER ___, 2019
(Filed With SEC on May 24, 2019)
-
Form of Secured Convertible Note, dated February 4, 2019
(Filed With SEC on February 6, 2019)
